Ian Leitch - Opthea Director Research

Opthea Management Efficiency

The company has Return on Asset of (0.8343) % which means that on every $100 spent on assets, it lost $0.8343. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (33.8308) %, meaning that it generated no profit with money invested by stockholders. Opthea's management efficiency ratios could be used to measure how well Opthea manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.22 in 2024. Return On Capital Employed is likely to gain to -1.46 in 2024. At this time, Opthea's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 198.2 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39.8 M in 2024.

Similar Executives

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. Opthea operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Opthea (OPT) is traded on NASDAQ Exchange in USA. It is located in 650 Chapel Street, South Yarra, VIC, Australia, 3141 and employs 33 people. Opthea is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Opthea Leadership Team

Opthea Stock Performance Indicators

Additional Tools for Opthea Stock Analysis